Cookson Peirce & Co. Inc. Has $1.27 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cookson Peirce & Co. Inc. lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 34.1% during the 4th quarter, Holdings Channel reports. The firm owned 3,750 shares of the medical equipment provider’s stock after selling 1,939 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Intuitive Surgical were worth $1,265,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Main Street Research LLC raised its holdings in shares of Intuitive Surgical by 96.6% in the fourth quarter. Main Street Research LLC now owns 73,132 shares of the medical equipment provider’s stock valued at $24,672,000 after buying an additional 35,935 shares during the last quarter. Guerra Pan Advisors LLC raised its holdings in shares of Intuitive Surgical by 10.7% in the fourth quarter. Guerra Pan Advisors LLC now owns 897 shares of the medical equipment provider’s stock valued at $303,000 after buying an additional 87 shares during the last quarter. DGS Capital Management LLC raised its holdings in shares of Intuitive Surgical by 20.8% in the fourth quarter. DGS Capital Management LLC now owns 867 shares of the medical equipment provider’s stock valued at $292,000 after buying an additional 149 shares during the last quarter. Keel Point LLC raised its holdings in shares of Intuitive Surgical by 3.6% in the fourth quarter. Keel Point LLC now owns 1,258 shares of the medical equipment provider’s stock valued at $424,000 after buying an additional 44 shares during the last quarter. Finally, Sentry Investment Management LLC raised its holdings in Intuitive Surgical by 62.0% during the 4th quarter. Sentry Investment Management LLC now owns 3,303 shares of the medical equipment provider’s stock worth $1,114,000 after purchasing an additional 1,264 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Truist Financial boosted their target price on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Citigroup boosted their target price on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Mizuho boosted their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $375.70.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,168,656.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the transaction, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,168,656.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 248,418 shares of company stock worth $95,927,097. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Stock Up 0.3 %

Shares of Intuitive Surgical stock opened at $378.55 on Wednesday. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The stock has a market cap of $134.18 billion, a P/E ratio of 75.26, a P/E/G ratio of 5.86 and a beta of 1.36. The business’s 50 day moving average is $387.90 and its 200-day moving average is $342.17.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The company had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter in the prior year, the business posted $0.91 EPS. The business’s revenue was up 16.6% compared to the same quarter last year. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.